EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy of Standard‐Dose Omalizumab Against Chronic Urticaria: A Real‐World Study

Zijing Xiao, Duoqin Wang, Yanyun Shen, Yixin Shao, Lisi Peng, Taiyu Jin, Yiqi Zhu, Hui Tang

Dermatologic Therapy · 2025-01 · 2025 (1)

DOI: 10.1155/dth/8754260 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Dermatologic Therapy, online erschienen am 20.06.2025. Verfasst von Zijing Xiao und 7 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Shanghai Shenkang Hospital Development Center.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Omalizumab has been recommended for the treatment of CU. Meanwhile, real‐world data are available on the efficacy and safety of omalizumab in patients with CSU, but there is a relative paucity of data on the use of the drug in the treatment of CIndU and CSU combined with CIndU.

Objective

To evaluate the efficacy and safety of omalizumab in Chinese patients with CSU, CholU, SDerm, or both, who had an inadequate response to H1‐antihistamine treatment.

Methods

This was an observational, retrospective chart review of patients with CU initiating omalizumab treatment.

Results

In total, 78.4% ( n = 80/102) of patients showed a response to omalizumab at the end of the study period, and 36.3% ( n = 37/102) showed a complete response. Among patients with different subtypes, 84.8% ( n = 38/45) of CSU, 37.5% ( n = 3/8) of CholU, 50% ( n = 1/2) of SDerm and 80.9% ( n = 38/47) of CSU + SDerm comorbidity subgroup patients showed a response. The mean of tIgE levels of responders were significantly higher than nonresponders (649.48 ± 814.69 vs. 264.27 ± 262.49 ng/mL, p = 0.004). Patients with isolated CSU exhibited significantly lower relapse rates compared to the CSU + SDerm comorbidity subgroup (42.9% vs. 57.1%, p = 0.042). In total, 12 patients reinitiated omalizumab treatment after a relapse and all of them showed an early response. The mean response time was 1.33 ± 0.65 months. The response mode was similar with their first treatment.

Conclusion

Omalizumab is effective in difficult‐to‐treat patients with CSU and CSU + SDerm comorbidity subgroup, but the response rates in patients with isolated CholU or SDerm are unsatisfactory. The mean of tIgE levels of responders were significantly higher than nonresponders at baseline. Patients in the CSU + SDerm comorbidity subgroup demonstrate an elevated risk of relapse. These findings support omalizumab’s role in refractory CSU and comorbid CSU + SDerm, but highlight unmet needs in isolated CIndU subtypes.

Förderung

  • National Natural Science Foundation of China
  • Shanghai Shenkang Hospital Development Center

Zitieren

APA

Xiao, Z., Wang, D., Shen, Y., Shao, Y., Peng, L., Jin, T., Zhu, Y., & Tang, H. (2025). Efficacy of Standard‐Dose Omalizumab Against Chronic Urticaria: A Real‐World Study. Dermatologic Therapy, 2025(1). https://doi.org/10.1155/dth/8754260

Vancouver

Xiao Z, Wang D, Shen Y, Shao Y, Peng L, Jin T, et al. Efficacy of Standard‐Dose Omalizumab Against Chronic Urticaria: A Real‐World Study. Dermatologic Therapy. 2025;2025(1). doi:10.1155/dth/8754260

BibTeX
@article{Xiao2025,
  author = {Xiao, Zijing and Wang, Duoqin and Shen, Yanyun and Shao, Yixin and Peng, Lisi and Jin, Taiyu and Zhu, Yiqi and Tang, Hui},
  title = {Efficacy of Standard‐Dose Omalizumab Against Chronic Urticaria: A Real‐World Study},
  journal = {Dermatologic Therapy},
  year = {2025},
  volume = {2025},
  number = {1},
  doi = {10.1155/dth/8754260}
}
Kostenlos starten →